Immune Panel

The Problem:​

Immune checkpoint inhibitors (ICI) have proven to be highly effective and durable therapies in only a small subset of cancer patients. However, predicting will respond to ICIs and benefit from this therapy has been a challenge thus far.​

Our Solution:​

We have developed an assay that assesses an RNA signature in order to predict whether a patient will respond to ICI therapy. This diagnostic will be critical in selecting the right patients for this treatment— thereby sparing those who would not benefit from undergoing an expensive and treatment-delaying regimen.